Würzburg Dynamics Secures RMB 100 Million Series A Funding to Advance Global Leadership in Soft Tissue Interventional Surgical Robotics

VCBeat learned at the earliest opportunity that 12Month27On the third anniversary of its registration and establishment,Shenzhen WeiDe Precisely Medical Technology Ltd.(abbreviated as“"Würzburg Dynamics") announced in 202210Month8Daily Completion1RMB 100 million exactlyARound of financing. This round of financing was led by a professional healthcare investment institution3E BioventuresLead Investor，Suizi FinanceandFosun Health CapitalCo-investment，Hanneng InvestmentServed as the exclusive financial advisor. The proceeds from this financing round will be used to accelerate the R&D of the company’s multi-pipeline percutaneous interventional surgical robots and to drive market development for its products.

Würzburg Dynamics was co-founded by a team of PhD holders who returned to China after studying or working abroad, with prior experience at globally renowned enterprises and academic institutions such as Siemens (Germany), Philips (China), the Max Planck Institute (Germany), Heidelberg University (Germany), and the University of Bern (Switzerland). The team possesses extensive R&D experience and industrial resources. Within less than three years since its establishment, the company has rapidly assembled talent across various fields, including medical imaging, artificial intelligence, software and hardware development, and advanced equipment manufacturing. Leveraging years of accumulated expertise and rapid iteration, it has developed a core technology platform centered on 3D reconstruction, surgical planning, intraoperative registration, surgical navigation, and robotic arm control, resulting in the successful development of percutaneous interventional surgical robots for lung and kidney procedures. Notably, Würzburg Dynamics is alsoThe only company in China to master both intraoperative CT-based and intraoperative ultrasound-based technological pathwayssurgical robotics companies.

From the perspective of the global surgical robotics industry landscape, pioneer companies have already emerged in sectors such as endoscopic surgery, orthopedics, neurosurgery, and vascular intervention, achieving favorable market reception; indeed, some of these sectors have already formed a relatively stable competitive structure. In the field of soft tissue intervention, percutaneous interventional procedures are widely applied across various organs, including the lungs, kidneys, and liver. However, physicians still face significant challenges, such as imprecise positioning, substantial operational errors, high radiation exposure risks, and frequent intraoperative complications. These pain points present substantial opportunities for the entry and implementation of surgical robotics in this domain.

Addressing clinical pain points in percutaneous soft tissue interventions, such as reduced surgical precision due to patients’ spontaneous breathing under local anesthesia and the inability of intraoperative imaging to automatically identify target sites in real time, Würzburg Dynamics offers a comprehensive, high-precision, fully automated solution for soft tissue interventional surgery. Built upon a closed-loop technological framework integrating preoperative planning, intraoperative guidance, and robotic arm systems, this solution assists clinicians in enhancing surgical precision, safety, and convenience, while significantly improving operational efficiency and shortening the learning curve. Currently, the surgical accuracy of Würzburg Dynamics’ soft tissue interventional surgical robot can approachSub-millimeter level, ranking among the industry's first tier.

In addition to its existing pipeline, Würzburg Dynamics’ precision technology platform demonstrates strong scalability. It can expand from percutaneous interventional procedures in the lungs and kidneys to soft tissues in multiple other anatomical regions, and extend its portfolio from percutaneous needle biopsy, ablation, and seed implantation to multi-procedural applications via natural orifices. With the successful closing of this round of financing, Würzburg Dynamics will continue to deliver clinical value while advancing further toward its goal of becoming a globally leading enterprise in soft-tissue interventional surgical robotics.

Dr. Xie Weiguo, Founder & CEO of Würzburg DynamicsIt was stated that interventional surgical robots for soft tissues (including the lungs, kidneys, liver, thyroid, and breasts) have undergone more than two decades of development. Driven by urgent clinical needs and through the joint efforts of international peers, these systems have progressed through three phases: basic research, application prototyping, and product development. They are now at the critical threshold of industrialization. Leveraging the founding team’s extensive professional experience in Germany and Switzerland, along with their solid technological accumulation, Würzburg Dynamics has entered the field via percutaneous soft tissue intervention procedures. The company has effectively addressed key challenges such as lesion displacement caused by intraoperative deformation and movement of soft tissue organs, fully automated real-time AI-based soft tissue image processing, multi-dimensional real-time registration of multimodal data during surgery, and intelligent human-machine collaboration. By establishing a closed technological loop that enables a closed-loop clinical application workflow, Würzburg Dynamics has achieved certain advantages in terms of clinical precision, safety, convenience, and real-time efficiency. With independent core technologies, a comprehensive intellectual property system, and a scientific and mature R&D framework, the company plans to gradually expand its pipeline to include robotic systems for natural orifice transluminal endoscopic surgery (NOTES) in soft tissues, thereby covering the entire spectrum of soft tissue interventional surgery.

In this round of financing, we extend our gratitude to the Hanneng team for their deep sector expertise and timely, efficient professional services. We also thank 3E Bioventures, Suizi Finance, and Fosun Health Capital for their recognition and empowerment of Würzburg Dynamics, demonstrated through their professional insight, steadfast confidence, and abundant industrial resources. It is our honor to embark on this journey together.We believe that the medical precision, surgical standardization, and homogenization of clinical resources driven by surgical robots represent an irreversible industry trend. Würzburg Dynamics looks forward to collaborating with clinicians and industry peers to advance the development of intelligent surgical robotics, including soft-tissue interventional surgical robots, thereby delivering greater benefits to patients, enhanced value to clinical practice, and improved societal outcomes.”

Geng Xiangnan, Investment Director at 3E BioventuresHe stated, “Achieving intelligent and standardized surgery through robotics is one of the most significant development trends in future medical devices. We are highly optimistic about percutaneous interventional surgical robots, which assist physicians in performing higher-precision procedures such as puncture and ablation, thereby addressing unmet clinical needs. We also believe in their potential to facilitate the decentralization of high-quality medical services and deliver broader clinical benefits to society. The Würzburg Dynamics team possesses profound technical expertise and deep clinical insights in surgical robotics and other fields, complemented by extensive industry resources and efficient execution capabilities. We hope the company will leverage these advantages to collaborate closely with clinical practitioners, refining excellent products that meet physicians’ needs and serve patients across China.”

Ni Xinliang, Investment Director of the Healthcare Team at Suizi FinanceIt stated: “As an emerging industry, surgical robotics started relatively late in China; however, driven by both technological advancements and supportive policies, the domestic market is currently experiencing rapid growth. Suizi Finance has consistently focused on exploring the applications of surgical robots across various surgical specialties. The percutaneous intervention field presents substantial market potential while also facing urgent clinical pain points that require immediate solutions. Dr. Xie from Würzburg Dynamics, together with a top-tier team of industry experts, has addressed clinical challenges in areas such as percutaneous puncture through robotic and artificial intelligence technologies. This has advanced the development of precision medicine in clinical practice, benefiting both healthcare providers and patients, thereby demonstrating significant social value.”

Wang Yao, Managing Partner of Xingweilai Fund“As a leading technology company in the field of percutaneous puncture robots, Würzburg Dynamics’ executive team brings extensive experience in successfully developing liver tumor percutaneous puncture robots for overseas markets. By integrating this expertise with clinical practices in China, the company has developed a new-generation AI-assisted puncture surgical robot platform targeting multiple clinical indications. Star Future Venture Capital Fund is honored to participate in the investment in Würzburg Dynamics. Leveraging the fund shareholders’ robust medical industry resources and operational experience with the da Vinci Surgical System, we aim to accelerate the industrialization of Würzburg Dynamics’ products, enabling their widespread adoption across various hospitals and benefiting a broad population of patients in China.”

Liu Pengcheng, Co-Head of the Healthcare Group at Han Energy Investment Groupstated: “Our team has deeply cultivated the medical surgical robotics sector, viewing it as a classic ‘long slope with thick snow’ industry. The core team of Würzburg Dynamics possesses profound technical expertise and extensive clinical resources. The series of soft-tissue interventional surgical robots we have developed are continuously iterated to address key pain points in clinical practice. Our products demonstrate far-leading precision, real-time performance, and ease of use, offering clear value and scarcity. Furthermore, Würzburg Dynamics’ technology is applicable to multiple procedures across various indications, indicating significant growth potential and long-term competitiveness.”

3E Bioventures is a specialized fund dedicated to investing in globally leading life sciences and healthcare companies, with a focus on two key investment areas: cross-disciplinary innovative medical devices and diagnostic technologies, and innovative pharmaceuticals. The core founding team consists entirely of PhD holders in biomedical fields from overseas institutions, boasting years of practical experience in the pharmaceutical and biotechnology industries, as well as over a decade of successful investment and entrepreneurial experience both domestically and internationally. The team combines professional expertise, industry experience, and a global perspective.

3E Bioventures is a dual-currency fund manager operating in both RMB and USD. It has cumulatively invested in and incubated more than 80 domestic and international healthcare innovation enterprises, with offices in Beijing, Shanghai, and Silicon Valley. Upholding the vision of “building great healthcare companies and establishing an internationally recognized professional investment brand,” 3E Bioventures empowers outstanding entrepreneurial teams and delivers superior returns to its investors.

Suizi Finance, established in 2014, adheres to the philosophy of “Integrity, Humility, Professionalism, and Perseverance.” It is an investment firm specializing in healthcare and cross-border consumer markets. The firm has invested in and incubated over 50 companies, with strategic investments in innovative drug R&D, such as tumor immunotherapy, within the pharmaceutical sector, and in high-end medical devices, such as surgical robots, within the medical device industry.

Suizi Finance remains committed to supporting China’s industrial upgrading, focusing on cutting-edge medical technologies, and facilitating the domestic substitution of medical products in China. Guided by clinical needs and adhering to a “small but beautiful” investment philosophy, we are dedicated to creating long-term value for China’s healthcare industry.

Xing Future Fund is a healthcare venture capital fund under Fosun Health Capital. Leveraging the resources of Fosun Pharma and the broader Fosun healthcare ecosystem, the fund combines global professional investment expertise with deep operational capabilities in the healthcare industry. Its core team members possess over 20 years of experience in investment and industrial operation management within the healthcare sector. The fund focuses on early- to mid-stage investments in precision medicine, life sciences, and related fields, committed to discovering innovative medical technologies worldwide, aggregating industry resources, and providing full-lifecycle empowerment to its portfolio companies.